167 related articles for article (PubMed ID: 38813042)
1. Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry.
Karataş A; Pişkin Sağir R; Koca SS; Dalkiliç E; Can G; Pehlivan Y; Yazici A; Inanç N; Cefle A; Ertürk Z; Akar S; Şenel S; Birlik M; Akkoç N; Önen F
Turk J Med Sci; 2023; 53(5):1321-1329. PubMed ID: 38813042
[TBL] [Abstract][Full Text] [Related]
2. Body Mass Index and response to rituximab in rheumatoid arthritis.
Ottaviani S; Gardette A; Roy C; Tubach F; Gill G; Palazzo E; Meyer O; Dieudé P
Joint Bone Spine; 2015 Dec; 82(6):432-6. PubMed ID: 26184536
[TBL] [Abstract][Full Text] [Related]
3. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients.
Iannone F; Fanizzi R; Notarnicola A; Scioscia C; Anelli MG; Lapadula G
Joint Bone Spine; 2015 May; 82(3):187-91. PubMed ID: 25619156
[TBL] [Abstract][Full Text] [Related]
4. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
[TBL] [Abstract][Full Text] [Related]
5. Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.
Schulman E; Bartlett SJ; Schieir O; Andersen KM; Boire G; Pope JE; Hitchon C; Jamal S; Thorne JC; Tin D; Keystone EC; Haraoui B; Goodman SM; Bykerk VP;
Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1185-1191. PubMed ID: 29193840
[TBL] [Abstract][Full Text] [Related]
6. Body Mass Index Impact on Disease Activity, Clinical and Sonographic Remission Rates in Patients with Rheumatoid Arthritis.
Sapundzhieva T; Karalilova R; Batalov A
Curr Rheumatol Rev; 2019; 15(3):215-223. PubMed ID: 30499417
[TBL] [Abstract][Full Text] [Related]
7. The association between increased body mass index and response to conventional synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: results from the METEOR database.
Dey M; Zhao SS; Moots RJ; Bergstra SA; Landewe RB; Goodson NJ
Rheumatology (Oxford); 2022 Feb; 61(2):713-722. PubMed ID: 33930113
[TBL] [Abstract][Full Text] [Related]
8. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).
Iannone F; Courvoisier DS; Gottenberg JE; Hernandez MV; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Choquette D; Finckh A
Clin Rheumatol; 2017 Apr; 36(4):773-779. PubMed ID: 27966068
[TBL] [Abstract][Full Text] [Related]
9. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review.
Gialouri CG; Pappa M; Evangelatos G; Nikiphorou E; Fragoulis GE
Autoimmun Rev; 2023 Jul; 22(7):103357. PubMed ID: 37150489
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with sarcopenia in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study.
Nakayama M; Furuya T; Inoue E; Tanaka E; Ikari K; Yamanaka H; Harigai M
Clin Rheumatol; 2024 Jan; 43(1):521-526. PubMed ID: 37731082
[TBL] [Abstract][Full Text] [Related]
11. Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry.
Bergstra SA; Allaart CF; Vega-Morales D; De Buck M; Murphy E; Salomon Escoto K; Huizinga TWJ
RMD Open; 2020 Jun; 6(2):. PubMed ID: 32506054
[TBL] [Abstract][Full Text] [Related]
12. Body mass index and response to abatacept in rheumatoid arthritis.
Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Fautrel B; Palazzo E; Meyer A; Sibilia J; Dieudé P
Eur J Clin Invest; 2016 Dec; 46(12):1048-1052. PubMed ID: 27736006
[TBL] [Abstract][Full Text] [Related]
13. Biologic interventions for fatigue in rheumatoid arthritis.
Almeida C; Choy EH; Hewlett S; Kirwan JR; Cramp F; Chalder T; Pollock J; Christensen R
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD008334. PubMed ID: 27271314
[TBL] [Abstract][Full Text] [Related]
14. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
15. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
Kim SK; Choe JY; Park SH; Lee H
Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
[TBL] [Abstract][Full Text] [Related]
16. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry.
Vallejo-Yagüe E; Burkard T; Finckh A; Burden AM;
BMJ Open; 2024 Feb; 14(2):e074864. PubMed ID: 38331859
[TBL] [Abstract][Full Text] [Related]
18. Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate.
Kaeley GS; MacCarter DK; Pangan AL; Wang X; Kalabic J; Ranganath VK
J Rheumatol; 2018 Dec; 45(12):1628-1635. PubMed ID: 30173153
[TBL] [Abstract][Full Text] [Related]
19. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
[TBL] [Abstract][Full Text] [Related]
20. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
